Drugs / POTASSIUM SODIUM HYDROGEN CITRATE ANHYDROUS
POTASSIUM SODIUM HYDROGEN CITRATE ANHYDROUS
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable1 trial | ||||||
| — | NCT04352153 | Apr → Sep 2020 | urolithiasis | Ai Peng | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT03924596 Comparator | Sep 2019 → Sep 2020 | urolithiasis | Sultan Qaboos University | Unknown | No outcome recorded |
| — | NCT06814834 Comparator | Dec 2023 → Dec 2024 | nephrolithiasis | Cairo University | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | POTASSIUM SODIUM HYDROGEN CITRATE ANHYDROUS | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068764 ↗ |
| Known as | Cg 120 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068764 ↗ |
| Known as | potassium-sodium-hydrogen-citrate | “Patients received guidance for oral potassium-sodium-hydrogen-citrate (6:6:3:5) at a dosage of twenty milliequivalents three times every day” NCT06814834 ↗ |
| Known as | Solimok | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068764 ↗ |
| Known as | Uralyt-U | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04352153 ↗ |
| Modality | Small molecule | — CHEMBL6068764 ↗ |
| Route | Oral | “10g orally in 3 divided doses” NCT03924596 ↗ |